Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record.

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

Open access
Glassman, Adam R., Wells, John A., Josic, Kristin, Maguire, Maureen G., Antoszyk, Andrew N., Baker, Carl, Beaulieu, Wesley T., Elman, Michael J., Jampol, Lee M., Sun, Jennifer K. · 2020 · Ophthalmology

Abstract

Purpose: Assess follow-up treatment and clinical outcomes at 5 years in eyes initially treated with anti-VEGF therapy for center involved diabetic macular edema (CI-DME) in a 2-year randomized clinical trial. Design: Multicenter cohort study. Participants: Participants with DME and visual acuity (VA) 20/32 to 20/320 enrolled in DRCR.net Protocol T with visits 5 years after randomization (3 years after Protocol T completion). Methods: Participants were assigned randomly to aflibercept, bevacizumab, or ranibizumab with protocol-defined follow-up and retreatment for 2 years. Thereafter, participants were managed at clinician discretion and recalled for a 5-year visit. Main Outcome Measures: Anti-VEGF treatment, VA letter score, and central subfield thickness. Results: Sixty-eight percent (317 of 463) of eligible participants completed the 5-year visit. Between years 2 and 5, 68% (217 of 317) of study eyes received at least one anti-VEGF treatment (median [interquartile range] 4 [0, 12]). At 5 years, mean VA improved from baseline by 7.4 letters (95% confidence interval [CI]: 5.9 to 9.0), but decreased by 4.7 letters (95%CI: 3.3 to 6.0) between 2 and 5 years. When baseline VA was 20/50 to 20/320, mean 5-year VA was 11.9 letters (95%CI: 9.3 to 14.5) better than baseline, but 4.8 letters (95% CI: 2.5 to 7.0) worse than 2 years. When baseline VA was 20/32 to 20/40, mean 5-year VA was 3.2 letters (95% CI: 1.4 to 5.0) better than baseline, but 4.6 letters (95% CI: 3.1 to 6.1) worse than 2 years. Mean central subfield thickness decreased from baseline to 5 years by 154μm (95% CI: 142 to 166) and was stable between 2 and 5 years (−1 μm [95% CI: −12 to 9]). Conclusions: Among the two-thirds of eligible Protocol T participants who completed a 5-year visit, mean VA improved from baseline to 5 years without protocol-defined treatment after follow-up ended at 2 years. Although mean retinal thickness was similar at 2 and 5 years, mean VA worsened during this period. Additional investigation into strategies to improve long-term outcomes in eyes with DME seems warranted to determine if VA can be better maintained with different management approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2020.03.021

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 198

Metadata

Authors
Glassman, A. R., Wells, J. A., Josic, K., Maguire, M. G., Antoszyk, A. N., Baker, C., Beaulieu, W. T., Elman, M. J., Jampol, L. M., & Sun, J. K.
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2020-09
Volume
127
Issue
9
Pages
1201-1210
ISSN
0161-6420 (ISSN-L)
OpenAlex
W3013631675
Cited by
198
References
0
FWCI
16.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). https://app.cochat.ai/papers/10.1016/j.ophtha.2020.03.021
The paper
Glassman, A. R., Wells, J. A., Josic, K., Maguire, M. G., Antoszyk, A. N., Baker, C., Beaulieu, W. T., Elman, M. J., Jampol, L. M., & Sun, J. K. (2020). Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. https://doi.org/10.1016/j.ophtha.2020.03.021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.